Bortezomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor, Myeloma
Conditions
Brief summary
RATIONALE: Bortezomib may stop the growth of myeloma cells by blocking proteasome activity. Cyclophosphamide and dexamethasone may work in different ways to stop the growth of myeloma cells by stopping them from dividing or by killing the cells. Granulocyte Clone Stimulating Factor (G-CSF) possesses the ability to mobilize the plasma cells to detach from myeloma niche, so as to promote drug sensitivity. PURPOSE: This phase Ⅱ trial is to study how well combination of G-CSF, bortezomib, cyclophosphamide and dexamethasone works in treating patients with multiple myeloma.
Detailed description
Myeloma cells reside in specialised microenvironments, which is called myeloma niche. Myeloma niche provides important cell-cell interactions and signalling molecules that regulate localization and proliferation of myeloma cells. stromal cell-derived factor 1(SDF-1)/Chemokine (C-X-C Motif) Receptor 4 (CXCR4) plays an important role in this process. G-CSF is reported to induce stem cell mobilization by decreasing bone marrow SDF-1. Our in vitro study found that G-CSF enhanced bortezomib activity by inhibiting SDF-1/CXCR4. Myeloma patients treated with Bortezomib, Cyclophosphamide and Dexamethasone have achieved a relatively good response, with an ORR about 80% and complete remission about 40%. We hypothesized that G-CSF may mobilize myeloma cells from myeloma niches thus to enhance bortezomib activity.
Interventions
DRUGG-CSF
G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
DRUGBortezomib
Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
DRUGCyclophosphamide
Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
DRUGDexamethasone
Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
Sponsors
Second Affiliated Hospital of Soochow University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female, aged ≥18 years, ≤ 80 years. 2. Newly diagnosed multiple myeloma according to International Myeloma Working Group. 3. Relapsed or bortezomib resistant multiple myeloma (MM), who didn't received bortezomib during the last line of therapy for MM prior to this study. 4. Progressive disease according to International Myeloma Working Group. 5. Negative pregnancy test for female with reproductive ability. 6. Signed written informed consent.
Exclusion criteria
1. The patient has a history of other active malignancies within 3 years prior to study entry. 2. The patient exhibits evidence of clinically significant uncontrolled conditions including, but not limited to: uncontrolled systemic infection (viral, bacterial, or fungal). 3. Female patient is pregnant or breast-feeding. 4. Known infection with HIV, active Hepatitis B or Hepatitis C. 5. The patient has a history of prior toxicity from bortezomib, cyclophosphamide or dexamethasone that resulted in permanent discontinuation of treatments. 6. Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to study drug administration. 7. Uncontrolled hypertension (defined as systolic blood pressure\[BP\] \> 160 millimeters of mercury (mmHg) or diastolic BP \> 100mmHg). 8. Myocardial infarction or unstable angina within the past 6 months prior to study drug administration. Heart failure of New York Heart Association function Class Ⅲ or Ⅳ prior to study drug administration. 9. System illness or other severe concurrent disease or alcoholism, which, in the judgement of the investigator, would make inappropriate for entry into this study or interfere significantly with the proper assessment of safety and efficacy of investigational treatments. 10. Known or suspected of not being able to comply with the trial protocol. 11. Having been previously enrolled in this clinical trial. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) | 4 months | Defined as the portion of patients whose best response is equal to or better than partial response (PR), including stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR) according to International Myeloma Working Group (IMWG). Response was confirmed after every cycle of treatment. Stringent complete response (sCR): Normal free light chain (FLC) ration, plus criteria for complete response. Complete response (CR): Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in the bone marrow. Very Good Partial Response(VGPR): Positive immunofixation but negative electrophoresis; ≥90% reduction in serum M-component; Urine M-component ≤ 100mg per 24 hours. Partial Response (PR): ≥50% reduction in serum M-component and/or Urine M-component ≥90% reduction or \< 200mg per 24 hours. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment related adverse events. | participants will be followed for the duration of hospital stay, an expected average of 4 weeks | Adverse Events (AE) are assessed according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 3.0. The maximum grade for each type of AE will be recorded for each patient. Grade 1: Mild AE. Grade 2: Moderate AE. Grade 3: Severe AE. Grade 4: Life-threatening or disabling AE. Grade 5: Death related AE. |
| Overall Survival (OS) | 2 years | Survival time is defined as the time from registration to death due to any cause. |
| Progression Free Survival (PFS) | 2 years | PFS is defined as the time from registration to the earliest date of documented disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death. |
| Duration of Response (DOR) | 2 years | Duration of response will be calculated from the date of first evidence of response until the date of progression in the subset of patients with confirmed hematologic responses. |
Countries
China
Contacts
Primary Contactjinxiang fu, Doctor
Outcome results
None listed